Drug intelligence / Profile preview

Cystelia-M

Development stage: Unknown
Lead developer: Jagsonpal Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Cystelia-M is a combination small molecule formulation developed and marketed by Jagsonpal Pharmaceuticals for the management of gynaecological conditions, specifically polycystic ovary syndrome (PCOS). The product contains myo-inositol and D-chiro-inositol in a physiologically relevant 40:1 ratio, which function as insulin sensitizers to improve insulin resistance, restore ovulatory function, and correct hormonal imbalances. Additionally, it includes L-methylfolate, the active form of folic acid, to support healthy folate levels and reduce homocysteine, which is often elevated in women with PCOS. Cystelia-M is available as an oral tablet and is part of Jagsonpal's specialized women's healthcare portfolio in India.

Brand names: Cystelia-M

Targets

FOLR1 (FRα)INSR (Insulin receptor)

Beyond the preview

Go deeper on Cystelia-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystelia-M.

Explore the full profile